• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

日本癌症患者系统治疗的真实世界结局(德洲会真实世界数据项目:TREAD):一项全国队列研究的研究方案

Real-World Outcomes of Systemic Therapy in Japanese Patients with Cancer (Tokushukai REAl-World Data Project: TREAD): Study Protocol for a Nationwide Cohort Study.

作者信息

Shimoyama Rai, Imamura Yoshinori, Uryu Kiyoaki, Mase Takahiro, Fujimura Yoshiaki, Hayashi Maki, Ohtaki Megu, Ohtani Keiko, Shinozaki Nobuaki, Minami Hironobu

机构信息

Department of General Surgery, Shonankamakura General Hospital, Kamakura 247-8533, Japan.

Department of Medical Oncology and Hematology, Kobe University Graduate School of Medicine, Kobe 650-0017, Japan.

出版信息

Healthcare (Basel). 2022 Oct 28;10(11):2146. doi: 10.3390/healthcare10112146.

DOI:10.3390/healthcare10112146
PMID:36360487
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9690553/
Abstract

Cohort studies using large-scale databases have become increasingly important in recent years. The Tokushukai Medical Group is a leading medical group in Japan that includes 71 general hospitals nationwide from Hokkaido to Okinawa, with a total of 18,000 beds, and a unified electronic medical record system. This retrospective cohort study aims to evaluate the real-world outcomes of systemic therapy for Japanese patients with cancer using this merit of scale. All adult patients with cancer who received systemic therapy using a centrally registered chemotherapy protocol system at 46 hospitals from April 2010 to March 2020 will be identified (~48,850 patients). Key exclusion criteria include active double cancer and inadequate data extraction. Data will be obtained through electronic medical records, diagnosis procedure combination data, medical prescription data, and the national cancer registration system that includes sociodemographic variables, diagnostic and laboratory tests, concomitant drug prescriptions, cost, and overall survival. Kaplan-Meier estimates will be calculated for time-to-event analyses. Stratified/conventional Cox proportional hazards regression analyses will be conducted to examine the relationships between overall survival and related factors. Our findings provide important insights for future research directions, policy initiatives, medical guidelines, and clinical decision-making.

摘要

近年来,使用大规模数据库的队列研究变得越来越重要。德洲会医疗集团是日本领先的医疗集团,在全国范围内拥有71家综合医院,从北海道到冲绳,共有18,000张床位,并拥有统一的电子病历系统。这项回顾性队列研究旨在利用这种规模优势评估日本癌症患者全身治疗的真实世界结果。将确定2010年4月至2020年3月期间在46家医院使用集中注册化疗方案系统接受全身治疗的所有成年癌症患者(约48,850名患者)。主要排除标准包括活动性双癌和数据提取不充分。数据将通过电子病历、诊断程序组合数据、医疗处方数据以及包括社会人口统计学变量、诊断和实验室检查、伴随药物处方、费用和总生存在内的国家癌症登记系统获得。将计算Kaplan-Meier估计值用于事件发生时间分析。将进行分层/传统Cox比例风险回归分析,以检验总生存与相关因素之间的关系。我们的研究结果为未来的研究方向、政策举措、医学指南和临床决策提供了重要见解。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ce38/9690553/55a79154b837/healthcare-10-02146-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ce38/9690553/55a79154b837/healthcare-10-02146-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ce38/9690553/55a79154b837/healthcare-10-02146-g001.jpg

相似文献

1
Real-World Outcomes of Systemic Therapy in Japanese Patients with Cancer (Tokushukai REAl-World Data Project: TREAD): Study Protocol for a Nationwide Cohort Study.日本癌症患者系统治疗的真实世界结局(德洲会真实世界数据项目:TREAD):一项全国队列研究的研究方案
Healthcare (Basel). 2022 Oct 28;10(11):2146. doi: 10.3390/healthcare10112146.
2
The future of Cochrane Neonatal.考克兰新生儿协作网的未来。
Early Hum Dev. 2020 Nov;150:105191. doi: 10.1016/j.earlhumdev.2020.105191. Epub 2020 Sep 12.
3
Effect of adjuvant chemotherapy on survival benefit in stage III colon cancer patients stratified by age: a Japanese real-world cohort study.辅助化疗对年龄分层的 III 期结肠癌患者生存获益的影响:一项日本真实世界队列研究。
BMC Cancer. 2020 Jan 6;20(1):19. doi: 10.1186/s12885-019-6508-1.
4
Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.COVID-19 住院成人患者使用伊马替尼的安全性和疗效:一项随机对照试验研究方案的结构化总结。
Trials. 2020 Oct 28;21(1):897. doi: 10.1186/s13063-020-04819-9.
5
Real-World Survival Outcomes Associated With First-Line Immunotherapy, Targeted Therapy, and Combination Therapy for Metastatic Clear Cell Renal Cell Carcinoma.转移性透明细胞肾细胞癌的一线免疫治疗、靶向治疗和联合治疗的真实世界生存结局。
JAMA Netw Open. 2021 May 3;4(5):e2111329. doi: 10.1001/jamanetworkopen.2021.11329.
6
Virtualized clinical studies to assess the natural history and impact of gut microbiome modulation in non-hospitalized patients with mild to moderate COVID-19 a randomized, open-label, prospective study with a parallel group study evaluating the physiologic effects of KB109 on gut microbiota structure and function: a structured summary of a study protocol for a randomized controlled study.用于评估非住院轻中度 COVID-19 患者肠道微生物组调节的自然史和影响的虚拟化临床研究:一项随机、开放标签、前瞻性研究,平行组研究评估 KB109 对肠道微生物组结构和功能的生理影响:一项随机对照研究方案的结构化总结。
Trials. 2021 Apr 2;22(1):245. doi: 10.1186/s13063-021-05157-0.
7
Effectiveness of Interferon Beta 1a, compared to Interferon Beta 1b and the usual therapeutic regimen to treat adults with moderate to severe COVID-19: structured summary of a study protocol for a randomized controlled trial.干扰素 β1a 对比干扰素 β1b 和常规治疗方案治疗中重度 COVID-19 成人患者的效果:一项随机对照试验研究方案的结构化总结。
Trials. 2020 Jun 3;21(1):473. doi: 10.1186/s13063-020-04382-3.
8
Study Design of the Nationwide Japanese Lead Extraction (J-LEX) Registry: Protocol for a Prospective, Multicenter, Open Registry.日本全国性铅取出(J-LEX)注册研究的设计:一项前瞻性、多中心、开放性注册研究的方案
J Arrhythm. 2020 Jul 10;36(5):849-853. doi: 10.1002/joa3.12396. eCollection 2020 Oct.
9
10
Real-world Overall Survival Using Oncology Electronic Health Record Data: Friends of Cancer Research Pilot.利用肿瘤电子健康记录数据进行真实世界的总生存分析:癌症研究之友的试点研究。
Clin Pharmacol Ther. 2022 Feb;111(2):444-454. doi: 10.1002/cpt.2443. Epub 2021 Nov 2.

引用本文的文献

1
Real-world evidence on the survival benefit of immune checkpoint inhibitors in combination with cytotoxic chemotherapy for patients with extensive-disease small-cell lung cancer: the Tokushukai Real World Data Project (TREAD) 06.免疫检查点抑制剂联合细胞毒性化疗对广泛期小细胞肺癌患者生存获益的真实世界证据:德洲会真实世界数据项目(TREAD)06
BMC Cancer. 2025 Aug 27;25(1):1379. doi: 10.1186/s12885-025-14701-z.
2
Analysis of aPTT predictors after unfractionated heparin administration in intensive care units using machine learning models.使用机器学习模型分析重症监护病房中普通肝素给药后的活化部分凝血活酶时间预测因素。
PLoS One. 2025 Jul 21;20(7):e0328709. doi: 10.1371/journal.pone.0328709. eCollection 2025.
3

本文引用的文献

1
Impact of the COVID-19 pandemic on the diagnosis of cancer in Japan: analysis of hospital-based cancer registries.COVID-19 大流行对日本癌症诊断的影响:基于医院癌症登记的分析。
Jpn J Clin Oncol. 2022 Oct 6;52(10):1215-1224. doi: 10.1093/jjco/hyac129.
2
Protocol for data extraction: how real-world data have been used in the National Institute for Health and Care Excellence appraisals of cancer therapy.数据提取方案:国家卫生与保健卓越研究所(NICE)对癌症疗法评估中如何使用真实世界数据。
BMJ Open. 2022 Jan 6;12(1):e055985. doi: 10.1136/bmjopen-2021-055985.
3
Cancer Therapy Guided by Mutation Tests: Current Status and Perspectives.
Machine learning-based prediction of bleeding risk in extracorporeal membrane oxygenation patients using transfusion as a surrogate marker.
以输血作为替代标志物,基于机器学习预测体外膜肺氧合患者的出血风险。
Transfusion. 2025 Jun;65(6):1051-1060. doi: 10.1111/trf.18261. Epub 2025 Apr 25.
4
Public assistance and survival equality in patients with EGFR mutation-positive lung cancer.表皮生长因子受体(EGFR)突变阳性肺癌患者的公共援助与生存平等
Jpn J Clin Oncol. 2025 Mar 5;55(3):228-236. doi: 10.1093/jjco/hyae167.
5
Inflammation‑based prognostic markers in patients with advanced or recurrent gastric cancer treated with nivolumab: Tokushukai REAl‑world Data project 02 (TREAD 02).纳武利尤单抗治疗晚期或复发性胃癌患者的基于炎症的预后标志物:德洲会真实世界数据项目02(TREAD 02)
Mol Clin Oncol. 2024 Oct 3;21(6):90. doi: 10.3892/mco.2024.2788. eCollection 2024 Dec.
6
Impact of First-Line Osimertinib and Other EGFR-Tyrosine Kinase Inhibitors on Overall Survival in Untreated Advanced EGFR-Mutated Non-small Cell Lung Cancer in Japan: Updated Data from TREAD Project 01.日本未经治疗的晚期 EGFR 突变型非小细胞肺癌一线奥希替尼和其他 EGFR 酪氨酸激酶抑制剂对总生存期的影响:来自 TREAD 项目 01 的更新数据。
Target Oncol. 2024 Nov;19(6):925-939. doi: 10.1007/s11523-024-01094-5. Epub 2024 Sep 20.
7
A cross domain access control model for medical consortium based on DBSCAN and penalty function.基于 DBSCAN 和罚函数的医疗联盟跨域访问控制模型。
BMC Med Inform Decis Mak. 2024 Sep 16;24(1):260. doi: 10.1186/s12911-024-02638-5.
8
Analysis of thromboembolism and prognosis in metastatic pancreatic cancer from the Tokushukai REAl‑world data project.来自德洲会真实世界数据项目的转移性胰腺癌血栓栓塞及预后分析
Mol Clin Oncol. 2024 Aug 7;21(4):73. doi: 10.3892/mco.2024.2771. eCollection 2024 Oct.
9
Prognostic impact of concomitant pH-regulating drugs in patients with non-small cell lung cancer receiving epidermal growth factor receptor tyrosine kinase inhibitors: the Tokushukai REAl-world Data project 01-S1.在接受表皮生长因子受体酪氨酸激酶抑制剂治疗的非小细胞肺癌患者中,联合使用pH调节药物的预后影响:德洲会真实世界数据项目01-S1
Cancer Chemother Pharmacol. 2024 Aug;94(2):197-208. doi: 10.1007/s00280-024-04666-4. Epub 2024 Apr 8.
10
Inflammation‑based prognostic markers of metastatic pancreatic cancer using real‑world data in Japan: The Tokushukai REAl‑world Data (TREAD) project.利用日本真实世界数据的转移性胰腺癌基于炎症的预后标志物:德洲会真实世界数据(TREAD)项目
Oncol Lett. 2024 Jan 31;27(3):136. doi: 10.3892/ol.2024.14269. eCollection 2024 Mar.
基于突变测试的癌症治疗:现状与展望。
Int J Mol Sci. 2021 Oct 10;22(20):10931. doi: 10.3390/ijms222010931.
4
Evaluating eligibility criteria of oncology trials using real-world data and AI.利用真实世界数据和人工智能评估肿瘤学试验的入组标准。
Nature. 2021 Apr;592(7855):629-633. doi: 10.1038/s41586-021-03430-5. Epub 2021 Apr 7.
5
Progression-free survival in oncological clinical studies: Assessment time bias and methods for its correction.肿瘤学临床研究中的无进展生存期:评估时间偏倚及其校正方法。
Pharm Stat. 2021 Jul;20(4):864-878. doi: 10.1002/pst.2115. Epub 2021 Mar 29.
6
History and Profile of Diagnosis Procedure Combination (DPC): Development of a Real Data Collection System for Acute Inpatient Care in Japan.诊断程序组合(DPC)的历史和概况:日本急性住院护理真实数据采集系统的开发。
J Epidemiol. 2021 Jan 5;31(1):1-11. doi: 10.2188/jea.JE20200288. Epub 2020 Nov 21.
7
Quality of Life of Cancer Patients Treated with Chemotherapy.癌症患者化疗后的生活质量。
Int J Environ Res Public Health. 2020 Sep 23;17(19):6938. doi: 10.3390/ijerph17196938.
8
Use of real-world data to study health services utilisation and comorbidities in long-term breast cancer survivors (the SURBCAN study): study protocol for a longitudinal population-based cohort study.利用真实世界数据研究长期乳腺癌幸存者的医疗服务利用情况和合并症(SURBCAN研究):一项基于人群的纵向队列研究方案
BMJ Open. 2020 Sep 9;10(9):e040253. doi: 10.1136/bmjopen-2020-040253.
9
Translating evidence into practice: eligibility criteria fail to eliminate clinically significant differences between real-world and study populations.将证据转化为实践:纳入标准未能消除真实世界人群与研究人群之间临床上的显著差异。
NPJ Digit Med. 2020 May 11;3:67. doi: 10.1038/s41746-020-0277-8. eCollection 2020.
10
Real-world studies no substitute for RCTs in establishing efficacy.在确定疗效方面,真实世界研究无法替代随机对照试验。
Lancet. 2019 Jan 19;393(10168):210-211. doi: 10.1016/S0140-6736(18)32840-X.